CHESTNUT RIDGE, N.Y., Nov. 15, 2017 /PRNewswire/ -- BioHiTech Global, Inc. ("BioHiTech" or the "Company") (OTCQB: BHTG), a green technology company that develops and deploys innovative and disruptive waste management technologies, reported financial results for the third quarter of 2017 ended September 30, 2017.
Business Highlights
"We continue to make significant progress on all business fronts as we position BioHiTech to deliver significant future value for our stockholders," said Frank E. Celli, CEO of BioHiTech. "We are excited to have begun delivery of our Revolution Series Digesters and are working diligently to ramp up our operations to meet current and anticipated demand. We are more confident than ever that we have unlocked a huge market opportunity with the Revolution Series and look forward to a progressive ramp up in revenue beginning in Q4 and the years to come. We have also forwarded our IIoT and data analytics technology innovation to solidify our competitive advantage and open new potential revenue streams while we continue to advance the development work for our planned HEBioT facility in New York. As we move through the remainder of 2017 and into 2018, we will continue to work toward our goal of establishing BioHiTech as the premier provider of cost effective and environmentally friendly technology solutions for waste management."
Q3 Financial Highlights
Revenue: Revenue in Q3 2017 reached $656,000, a 5% increase compared to revenue of $624,000 in Q3 2016, and a 20% increase compared to revenue of $549,000 in Q2 2017. Recurring rental, service and maintenance grew by 15.8% year over year to reach $415,000, accounting for 63.3% of total revenue.
Gross Profit: Q3 2017 gross profit was $155,000 compared to $191,000 in Q3 2016. The decline in gross margin and profit was mainly attributable due to the change in mix of revenue between equipment sales and rental, service and maintenance, as well as a higher level of installation costs, partly due to the initial roll-out of the Revolution Series of digesters with trial periods with several large national chain stores. The Company expects to see an improvement in installation costs and gross margin in Q4 2017.
Operating Expenses: Q3 2017 operating expenses were $1.9 million, a 19.7% increase compared to $1.6 million in Q3 2017, which was primarily driven by an increase in professional services and personnel related costs to support marketing and investor relations.
Operating Loss: Q3 2017 operating loss was $1.8 million compared to $1.6 million in Q3 2016. The increase in operating loss was primarily driven by the increase in operating expenses.
Net Loss: Q3 2017 net loss was $2.3 million compared to $1.4 million in Q3 2016, which was due to the increased loss from operations and increased interest expense.
Year to Date September 30, 2017
Revenue: In the first nine months, 2017 revenue was $1.8 million, a 16.8% increase from $1.5 million in 2016. Recurring rental, service and maintenance grew by 14.5% and represented 63.5% of total revenue. Revenue from sales of equipment increased by 21.1% and represented 36.5% of revenue in 2017.
Gross Profit: In the first nine months, 2017 gross profit was $525,000, a 32.8% increase from $395,000 in 2016. Gross margin was 29.2% in the first nine months, 2017, an increase of 350 basis points compared to gross margin of 25.7% in comparable 2016 period.
Operating Expenses: In the first nine months, 2017 operating expenses increased by 14.9% to $5.5 million compared to $4.8 million in 2016. The increase was primarily driven by a continued focus on professional services supporting investor relations and marketing.
Operating Loss: In the first nine months, 2017 operating loss increased by $586,000 to $5.0 million, primarily due to the increase in operating expenses described above.
Net Loss: In the first nine months, 2017 the net loss of $6.2 million increased by $1.2 million due primarily to a $715,000 increase in operating costs driven by professional fees, a $658,000 increase in other expenses primarily driven by interest expense, partially offset by a $130,000 improvement in gross profit.
Cash flows: In the first nine months, 2017 cash flow utilized in operations of $3.8 million increased by 4.9% from $3.7 million in 2016. Stock based compensation to employees and service providers increased from $512,000 in 2016 to $1,247,000 in 2017. Cash flows utilized in investing activities increased in 2017 to $1.2 million, from $4,000 in 2016 primarily due its MBT investment in West Virginia. Cash flow from financing activities increased from $3.7 million in 2016 to $5.1 million in 2017 due to increased borrowings to support operations and investing activities.
Brian C. Essman, CFO commented, "We continue to achieve top line revenue growth, particularly in revenue derived from recurring rental, service and maintenance contracts. While the Revolution Series Digester roll out has resulted in an initial increase in costs, we expect to see costs return to more normalized levels in the coming quarters as we benefit from a rapidly growing installed base. We successfully raised capital to support our growth plan and continue to work to prudently manage our resources while we grow our business. We expect our Revolution Series Digesters to begin contributing revenue in Q4 2017 and for that revenue to build progressively throughout 2018. We remain committed to the implementation of our aggressive long-term growth plans to enable us to deliver substantial long-term value for our stockholders."
About BioHiTech Global
BioHiTech Global (OTCQB:BHTG), "The Company" headquartered in Chestnut Ridge NY, develops and deploys innovative and disruptive waste management technologies. The combined offerings of BioHiTech Global offer our customers a full suite of technology based disposal options capable of having a significant impact on waste generation while providing a true zero landfill environment. With options for both on and off site biological treatment of waste, BioHiTech Global is a leader in zero waste solutions for businesses and municipalities. For more information, please visit www.biohitech.com.
Forward Looking Statements
Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance. These statements may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of BioHiTech Global, Inc. to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. BioHiTech Global, Inc. assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission ("SEC"). There may be other factors not mentioned above or included in the BioHiTech's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement. BioHiTech Global, Inc. assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.
Company Contact:
BioHiTech Global, Inc.
Lisa Giovannielli
Director, Corporate Communications
Direct: 845-262-1081
[email protected]
www.biohitech.com
BioHiTech Global, Inc. and Subsidiaries | |||||||||||||||||
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) | |||||||||||||||||
Three Months Ended September 30, |
Nine Months Ended September 30, | ||||||||||||||||
2017 |
2016 |
2017 |
2016 | ||||||||||||||
Revenue |
|||||||||||||||||
Rental, service and maintenance |
$ |
415,402 |
$ |
358,625 |
$ |
1,140,751 |
$ |
996,179 | |||||||||
Equipment sales |
240,945 |
264,953 |
655,493 |
541,407 | |||||||||||||
Total revenue |
656,347 |
623,578 |
1,796,244 |
1,537,586 | |||||||||||||
Cost of revenue |
|||||||||||||||||
Rental, service and maintenance |
348,862 |
256,107 |
880,559 |
761,834 | |||||||||||||
Equipment sales |
151,998 |
176,511 |
391,152 |
380,684 | |||||||||||||
Total Cost of revenue |
500,860 |
432,618 |
1,271,711 |
1,142,518 | |||||||||||||
Gross profit |
155,487 |
190,960 |
524,533 |
395,068 | |||||||||||||
Operating expenses |
|||||||||||||||||
Selling, general and administrative |
1,090,003 |
983,725 |
3,211,855 |
3,171,973 | |||||||||||||
Research and development |
207,258 |
242,435 |
611,582 |
661,529 | |||||||||||||
Professional fees |
604,225 |
356,652 |
1,618,076 |
894,386 | |||||||||||||
Depreciation and amortization |
27,674 |
29,174 |
85,781 |
84,122 | |||||||||||||
Total operating expenses |
1,929,160 |
1,611,986 |
5,527,294 |
4,812,010 | |||||||||||||
Loss from operations |
(1,773,673) |
(1,421,026) |
(5,002,761) |
(4,416,942) | |||||||||||||
Other expense (income) |
|||||||||||||||||
Equity loss in affiliate |
5,922 |
- |
11,838 |
- | |||||||||||||
Loss on change in fair value of warrants |
- |
- |
1,999 |
- | |||||||||||||
Interest income |
(712) |
- |
(713) |
(3,068) | |||||||||||||
Interest expense |
528,608 |
222,142 |
1,199,040 |
556,867 | |||||||||||||
Total other expense, net |
533,818 |
222,142 |
1,212,164 |
553,799 | |||||||||||||
Net loss |
(2,307,491) |
(1,643,168) |
(6,214,925) |
(4,970,741) | |||||||||||||
Other comprehensive (loss) income |
|||||||||||||||||
Foreign currency translation adjustment |
(15,891) |
4,098 |
(44,395) |
10,498 | |||||||||||||
Comprehensive loss |
$ |
(2,323,382) |
$ |
(1,639,070) |
$ |
(6,259,320) |
$ |
(4,960,243) | |||||||||
Net loss per share - basic and diluted |
$ |
(0.27) |
$ |
(0.20) |
$ |
(0.75) |
$ |
(0.60) | |||||||||
Weighted average number of common shares |
8,397,191 |
8,229,712 |
8,316,943 |
8,229,712 | |||||||||||||
BioHiTech Global, Inc. and Subsidiaries | |||||||
Condensed Consolidated Balance Sheets (Unaudited) | |||||||
September 30, |
December 31, | ||||||
2017 |
2016 | ||||||
Assets |
|||||||
Current Assets |
|||||||
Cash |
$ |
480,329 |
$ |
325,987 | |||
Accounts receivable, net |
234,669 |
140,130 | |||||
Inventory |
346,160 |
706,017 | |||||
Prepaid expenses and other current assets |
101,093 |
21,865 | |||||
Total Current Assets |
1,162,251 |
1,193,999 | |||||
Equipment on operating leases, net |
1,255,409 |
1,023,404 | |||||
Equipment, fixtures and vehicles, net |
45,096 |
54,356 | |||||
Intangible assets, net |
196,683 |
267,042 | |||||
Investment in Entsorga West Virginia, LLC |
1,022,190 |
- | |||||
MBT facility development costs |
139,313 |
- | |||||
Other assets |
23,500 |
13,500 | |||||
Total Assets |
$ |
3,844,442 |
$ |
2,552,301 | |||
Liabilities and Stockholders' Deficit |
|||||||
Current Liabilities: |
|||||||
Line of credit |
$ |
2,463,736 |
$ |
2,463,736 | |||
Accounts payable |
921,129 |
1,197,277 | |||||
Accrued expenses |
624,856 |
522,727 | |||||
Accrued interest |
925,790 |
411,917 | |||||
Deferred revenue |
109,183 |
61,879 | |||||
Notes payable, including related party of $275,000 |
- |
375,000 | |||||
Convertible note, net of deferred financing cost of $6,320 and discounts of $22,648 |
191,032 |
- | |||||
Convertible notes, including related party of $450,000, net of discounts of $310,814 |
939,186 |
- | |||||
Advance from related party |
544,777 |
1,213,027 | |||||
Customer deposits |
87,830 |
36,131 | |||||
Long-term debt, current portion |
6,282 |
8,525 | |||||
Total Current Liabilities |
6,813,801 |
6,290,219 | |||||
Promissory note, related party |
4,500,000 |
2,500,000 | |||||
Long-term debt, net of current portion |
6,922 |
11,048 | |||||
Notes payable, including related party of $275,000 |
375,000 |
- | |||||
Accrued interest, payable in cash or common stock |
615,468 |
253,000 | |||||
Unsecured subordinated mandatorily convertible notes, including related parties of |
7,673,461 |
4,956,134 | |||||
Total Liabilities |
19,984,652 |
14,010,401 | |||||
Commitments and Contingencies |
|||||||
Stockholders' Deficit |
|||||||
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; none issued |
- |
- | |||||
Common stock, $0.0001 par value, 50,000,000 shares authorized, 8,446,849 shares issued |
845 |
823 | |||||
Additional paid in capital |
11,181,512 |
9,604,324 | |||||
Accumulated deficit |
(27,287,091) |
(21,072,166) | |||||
Accumulated other comprehensive (loss) gain |
(35,476) |
8,919 | |||||
Total Stockholders' Deficit |
(16,140,210) |
(11,458,100) | |||||
Total Liabilities and Stockholders' Deficit |
$ |
3,844,442 |
$ |
2,552,301 |
BioHiTech Global, Inc. and Subsidiaries | |||||||
Condensed Consolidated Statements of Cash Flows (Unaudited) | |||||||
Nine Months Ended September 30, | |||||||
2017 |
2016 | ||||||
Cash flows from operating activities: |
|||||||
Net loss: |
$ |
(6,214,925) |
$ |
(4,970,741) | |||
Adjustments to reconcile net loss to net cash used in operations: |
|||||||
Depreciation and amortization |
299,021 |
331,807 | |||||
Provision for bad debts |
89,630 |
70,467 | |||||
Stock based employee compensation |
375,508 |
512,318 | |||||
Fees paid in stock and warrants |
871,531 |
- | |||||
Interest resulting from amortization of financing costs and discounts |
223,718 |
55,076 | |||||
Equity loss in affiliate |
11,838 |
- | |||||
Change in fair value of warrant liability |
1,999 |
- | |||||
Changes in operating assets and liabilities |
505,650 |
343,326 | |||||
Net cash used in operations |
(3,836,030) |
(3,657,747) | |||||
Cash flow from investing activities: |
|||||||
Sale of used machinery and equipment |
13,530 |
- | |||||
Investment in Entsorga West Virginia, LLC |
(1,034,028) |
- | |||||
Increase in MBT facility development costs |
(139,313) |
- | |||||
Purchases of equipment, fixtures and vehicles |
(6,057) |
(3,825) | |||||
Net cash used in investing activities |
(1,165,868) |
(3,825) | |||||
Cash flows from financing activities: |
|||||||
Net change in line of credit |
- |
(25,017) | |||||
Proceeds from convertible notes with warrants and beneficial conversion feature |
200,000 |
- | |||||
Proceeds from series convertible notes with warrants and beneficial conversion |
2,259,000 |
3,400,000 | |||||
Deferred financing costs incurred |
(23,000) |
(165,230) | |||||
Repayments of long-term debt |
(6,369) |
(6,170) | |||||
Related party: |
|||||||
Net increase (decrease) in advances |
1,120,756 |
203,027 | |||||
Proceeds from promissory notes |
786,973 |
526,973 | |||||
Repayments of promissory notes |
- |
(200,000) | |||||
Proceeds from series convertible notes |
800,000 |
- | |||||
Net cash provided by financing activities |
5,137,360 |
3,733,583 | |||||
Effect of exchange rate on cash |
18,880 |
64,897 | |||||
Net change in cash |
154,342 |
136,908 | |||||
Cash - beginning of period |
325,987 |
39,195 | |||||
Cash - end of period |
$ |
480,329 |
$ |
176,103 |
SOURCE BioHiTech Global, Inc.